AndrewCHarrisMD

Pediatric Hematology & Oncology • New York, NY

Associate Attending - Memorial Sloan Kettering Cancer Center

Overview of Dr. Harris

Dr. Andrew Harris is a pediatric hematologist/oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 12 years. He is one of 95 doctors at Memorial Sloan Kettering Cancer Center who specialize in Pediatric Hematology & Oncology. He has more than 70 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(360) 492-1034

Education & Training

University of MichiganFellowship, Pediatric Hematology/Oncology, 2008 - 2011
Cleveland Clinic FoundationResidency, Pediatrics, 2005 - 2008
Case Western Reserve University School of MedicineClass of 2005

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2021 - 2026
UT State Medical License 2015 - 2022
MI State Medical License 2008 - 2018
OH State Medical License 2005 - 2008
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Publications & Presentations

PubMed

41 citations
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol...
Maureen M O'Brien, Lingyun Ji, Nirali N Shah, Susan R Rheingold, Deepa Bhojwani
Journal of Clinical Oncology. 2022-03-20
107 citations
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
Benjamin Watkins, Muna Qayed, Courtney McCracken, Brandi Bratrude, Kayla Betz
Journal of Clinical Oncology. 2021-01-15
294 citations
ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death
Mark Vander Lugt, Thomas Braun, Samir M. Hanash, Jerome Ritz, Vincent T. Ho
The New England Journal of Medicine. 2013-08-07

Abstracts/Posters

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
Andrew C Harris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
Andrew C. Harris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019